A client’s new chemical entity showed potential for breakthrough status. Working together, we amended their CMC strategy at Phase 1 to support commercial-scale quantities.
Impact for the client:
- Breakthrough drug status granted
- CMC comparability simplified
- Phase 1 clinical lots reused for later filings
- Approval accelerated by 3 to 6 months
